Frontlight ResearchEarly access
Metastatic breast cancer trials in France
79 of 83 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in FranceMulticenter phase III non-Inferiority trial of treatment reduction in patients with advanced hormonesensitive breast cancer in complete response
- Where
- Amiens Cedex 1, Angers, Avignon Cedex 9, Bayonne, Bordeaux, Caen Cedex 5, Clermont Ferrand Cedex 2, Dijon, Epagny Metz-tessy, Lille, Limoges, Lyon, Marseille, Montpellier Cedex 5, Nice Cedex 2, Orleans Cedex 2, Paris, Paris Cedex 13, Plérin, Reims, Rennes Cedex, Saint-Cloud, Saint-Herblain Cedex, Saint Nazaire Cedex, Strasbourg, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex
- Age
- 18 years and over
- People
- 802
- Run by
- Unicancer
See details and how to join2026-526319-12-00 - Phase 1/2Taking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Bordeaux, Caen, Lyon, Marseille, Nice, Paris, Rennes, Saint-Herblain, Strasbourg, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - Phase 3Taking peopleEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Where
- Avignon Cedex 9, Besancon Cedex, Bordeaux, Caen Cedex 5, Le Mans Cedex 2, Lille, Lyon, Marseille, Pierre-Bénite, Poitiers, Rouen, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Where
- Avignon, Bayonne, Bordeaux Cedex, Dijon, Lille
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00 - Phase 1/2Taking peopleA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Where
- Besançon, Dijon, Le Mans, Saint-Herblain Cedex, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 380 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06827236 · EU 2024-517979-20-00 - Phase 1Not yet taking people in FranceRUPISTAR: A Study in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutation
- Where
- Lyon, Saint-Herblain Cedex
- Age
- 18 years and over
- People
- 6
- Run by
- Evexta Bio
See details and how to join2026-527387-33-00 - Phase 2Taking peopleASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Where
- Besançon, Bordeaux, Paris, Poitiers, Rennes, Villejuif
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- ALX Oncology Inc.
See details and how to joinNCT07007559 - Phase 3Taking peopleBGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
- Where
- Bordeaux, Lyon, Marseille, Montpellier Cedex 5, Rennes Cedex, Saint-Herblain Cedex, Villejuif
- Age
- 18 years and over
- People
- 233 worldwide
- Run by
- BeOne Medicines I GmbH
See details and how to joinNCT07492641 · EU 2025-523960-19-00 - Phase 1/2Taking peopleA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Where
- Lyon, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 1,132 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00 - Phase 3Taking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Angers, Besancon Cedex, Bobigny Cedex, Bordeaux, Caen Cedex 5, Dijon, Lyon, Marseille, Montpellier, Nice Cedex 2, Paris, Plerin, Saint-Cloud, Saint-Herblain Cedex, Thonon-Les-Bains, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, Vantoux, Villejuif
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - Phase 1Not yet taking people in FranceA Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- Where
- Poitiers, Villejuif Cedex
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- Pfizer
See details and how to joinNCT07318805 · EU 2025-524387-38-00 - Phase 2/3Taking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Grenoble, Lyon, Montpellier, Nice, Poitiers, Rennes, Toulouse
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Where
- Angers, Lille, Montpellier, Paris, Plerin, Poitiers, Rennes Cedex, Rouen Cedex, Saint-Cloud, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00 - Phase 3Not yet taking people in FranceA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Where
- Avignon, Besançon, Brest, Clermont-Ferrand, Dijon, Le Mans, Lyon, Montpellier, Paris, Plérin, Reims, Saint-Cloud, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif
- Age
- 18 years and over
- People
- 800 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00 - Phase 3Taking peopleA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Where
- Brest, Lyon, Rouen, Villejuif
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00 - Phase 2Taking peopleA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Where
- Lille, Lyon, Marseille, Montpellier Cedex 5, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00 - Phase 1Not yet taking people in FranceA Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- Where
- Lyon, Paris, Villejuif
- Age
- 18 years and over
- People
- 170 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07524855 · EU 2026-527749-23-00 - Phase 1Taking peopleStudy of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
- Where
- Marseille, Toulouse
- Age
- 18 years and over
- People
- 194 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07604571 - Phase 3Taking peopleA Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
- Where
- Avignon Cedex 9, Bordeaux, Brest, Caen Cedex 5, Clermont Ferrand Cedex1, Compiegne, Dijon, Le Mans, Lille, Lyon, Marseille, Montpellier Cedex 5, Nice Cedex 2, Paris, Plérin, Poitiers, Rennes Cedex, Rouen Cedex, Strasbourg, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 264 worldwide
- Run by
- Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00 - Phase 3Taking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Angers, Besancon Cedex, Lille, Lyon, Marseille, Paris, Rouen, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif Cedex
- Age
- 18 years and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - Phase 2Taking peopleDetecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
- Where
- Amiens, Amiens Cedex 1, Auxerre, Avignon Cedex 9, Bayonne, Beauvais, Beuvry, Blois Cedex, Boulogne-sur-Mer, Brest, Chalon Sur Saone Cedex, Cholet, Clermont Ferrand Cedex1, Clermont Ferrand Cedex 2, Contamine-sur-Arve, Coudekerque-Branche, Frejus, La Roche Sur Yon Cedex 9, Lyon, Marseille, Montpellier Cedex 5, Nancy, Neuilly-Sur-Seine, Nice Cedex 2, Nîmes, Paris, Pau Cedex, Plérin, Reims, Rennes Cedex, Saint-Grégoire, Strasbourg, Thonon-les-Bains, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Age
- 18 years and over
- People
- 80
- Run by
- UNICANCER
See details and how to joinNCT06680596 · EU 2024-515349-41-00 - Phase 3Active, not recruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Where
- Avignon, Bayonne, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Rennes Cedex, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Besancon Cedex, Bordeaux, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 1Not yet taking people in FranceA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Lyon, Marseille
- Age
- 18 years and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 - Phase 1Taking peopleA clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
- Where
- Marseille, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 40 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-522707-26-00